Cell Free Protein Expression Systems Patents: Who Holds the Core Claims
30.4% of all 996 records sit with just five assignees, so the foundational energy-regeneration and translation-system claims are already concentrated before a new entrant even files. Filings climbed to 118 in 2020, the high point of the dataset, before easing back — 95 in 2021 down to 40 in 2024, a -58% change over that span. 2025 and 2026 figures are still filling in under the usual 18-month publication lag, so the recent-looking drop should not be read as a shrinking field; it is a still-completing one.
- 1THE TRUSTEES OF THE UNIV OF PENNSYLVANIA87
- 2CELLSCRIPT LLC70
- 3THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV61
- 4MODERNATX INC43
- 5CUREVAC SE42
See the full cell free protein expression systems analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in cell free protein expression?
The ranked leader in this dataset holds 87 records, notably ahead of fifth place at 42 and tenth place at 23. The top five ranked assignees combined account for 30.4% of all 996 records in scope, and the leader set is dominated by research universities and mRNA-therapeutics companies rather than traditional biomanufacturing firms. This concentration is steepest at the very top and flattens out through the rest of the ranked list, which includes 100 companies in total.
Is filing activity in cell free expression systems growing or shrinking?
Filings peaked in 2020 at 118 and declined to 40 by 2024, a -58% change from the 95 filings recorded in 2021. That reads as a cooling from an unusually active peak year rather than a field going cold, and it should not be extended to 2025 or 2026: patent publication lags filing by roughly 18 months, so the most recent years in any dataset are always undercounted at the point of capture.
What does US9701993B2 actually cover?
US9701993B2, filed by The University of Tokyo and published in 2017, claims an artificial translation and synthesis system that adds tRNAs binding special amino acids into an in vitro translation reaction, using a dual genetic code table and an artificial codon box division to incorporate non-standard amino acids into synthesized peptides. It blocks approaches that rely on this specific dual-code, expanded-tRNA mechanism for non-standard amino acid incorporation in a cell free system. Systems using conventional amino acid sets or different expansion mechanisms are not automatically caught by it, but any workaround needs a careful claim-by-claim comparison rather than a design-around by assumption.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Cell Free Protein Expression Systems covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.